Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for CytomX Therapeutics (CTMX) over the last 10 years, with Q3 2025 value amounting to $46.6 million.

  • CytomX Therapeutics' Total Non-Current Liabilities fell 7059.86% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year decrease of 7059.86%. This contributed to the annual value of $116.9 million for FY2024, which is 5236.36% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Total Non-Current Liabilities is $46.6 million, which was down 7059.86% from $50.9 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Total Non-Current Liabilities registered a high of $346.6 million during Q4 2022, and its lowest value of $46.6 million during Q3 2025.
  • For the 4-year period, CytomX Therapeutics' Total Non-Current Liabilities averaged around $192.6 million, with its median value being $199.4 million (2024).
  • As far as peak fluctuations go, CytomX Therapeutics' Total Non-Current Liabilities tumbled by 655.61% in 2023, and later plummeted by 7269.77% in 2025.
  • Over the past 4 years, CytomX Therapeutics' Total Non-Current Liabilities (Quarter) stood at $346.6 million in 2022, then decreased by 29.22% to $245.3 million in 2023, then tumbled by 52.36% to $116.9 million in 2024, then plummeted by 60.16% to $46.6 million in 2025.
  • Its last three reported values are $46.6 million in Q3 2025, $50.9 million for Q2 2025, and $69.3 million during Q1 2025.